Chongqing Genrix Biopharmaceutical Co., Ltd. (SHA:688443)
China flag China · Delayed Price · Currency is CNY
23.75
-0.45 (-1.86%)
At close: Nov 17, 2026

SHA:688443 Cash Flow Statement

Millions CNY. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-209.44-535.65-797.27-801.32-576.37-322.13
Depreciation & Amortization
68.4868.4869.6459.1749.9438.5
Other Amortization
7.487.484.954.613.695.56
Loss (Gain) From Sale of Assets
4.514.510--0-
Asset Writedown & Restructuring Costs
0.390.390.54000.7
Loss (Gain) From Sale of Investments
-13.27-13.27-2.73-1.94-7.86-4.13
Provision & Write-off of Bad Debts
0.480.480.63---0.03
Other Operating Activities
-159.731.929.5134.0133.9932.15
Change in Accounts Receivable
6.066.06-40.889.88-7.71-105.1
Change in Inventory
-45.01-45.014.691.85-22.67-17.81
Change in Accounts Payable
136.72136.721.7351.155.87131.8
Change in Other Net Operating Assets
--153.76265.07293.472.68
Operating Cash Flow
-203.29-337.91-575.44-377.58-177.64-237.82
Operating Cash Flow Growth
------

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-105.26-85.42-45.32-90.98-146.21-112.7
Sale of Property, Plant & Equipment
0.070.10.04--0
Investment in Securities
-648.74-264.2-382.28211.6194.2-409.24
Other Investing Activities
12.38.830.14-3.41.12
Investing Cash Flow
-741.63-340.7-427.42120.6251.4-520.82

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Short-Term Debt Issued
-----73.32
Long-Term Debt Issued
-892.25212.91109.63208.35186.79
Total Debt Issued
879892.25212.91109.63208.35260.11
Short-Term Debt Repaid
------499.15
Long-Term Debt Repaid
--675.22-23.39-257.25-14.88-9.07
Lease Payments
-14.31-14.31-13.6-12-13.97-8.16
Total Debt Repaid
-1,005-675.22-23.39-257.25-14.88-508.22
Net Debt Issued (Repaid)
-126.14217.02189.52-147.62193.48-248.11
Issuance of Common Stock
---3,308-1,000
Repurchase of Common Stock
-5.62-5.62-14.68---
Common Dividends Paid
-30.7-30.51-28.67-35.02-32.1-21.59
Other Financing Activities
8.52---25.41--
Financing Cash Flow
-153.94180.88146.173,100161.37730.3

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
-0.060.01----
Net Cash Flow
-1,099-497.71-856.692,84335.13-28.34

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-308.55-423.33-620.75-468.56-323.85-350.52
Free Cash Flow Growth
------
Free Cash Flow Margin
-38.52%-183.48%-2062.65%-38675.98%-68143.75%-894.41%
Free Cash Flow Per Share
-0.93-1.15-1.69-1.46-1.18-1.27
Levered Free Cash Flow
-439.34-276.83-413.65-267.97-190.87-715.31
Unlevered Free Cash Flow
-423.81-257.2-395.59-246.1-170.4-695.05
Free Cash Flow After Leases
-322.86-437.63-634.35-480.56-337.82-358.68

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Income Tax Paid
8.267.794-21.69-57.48-17.5
Change in Working Capital
97.7797.77119.3327.89318.9711.57